16
Apr
2026
RevMed Nails RAS, Lilly Acquires CrossBridge, & IPOs Line Up
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Apr
2026
PhaseV Steps Up for Young Cancer Researchers
The Timmerman Traverse for Damon Runyon Cancer Research Foundation has a new major sponsor. PhaseV, the Boston-based company which provides AI/ML solutions to speed up and automate key aspects of clinical trials, has agreed to contribute $50,000 as the “Mt. Emerson” sponsor of this summer’s expedition in the High Sierras of California. This sponsorship could add up to much more.... Read More
13
Apr
2026
Big Monday: RevMed, Spyre, Ideaya, Allogene in the News
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Apr
2026
Gilead’s Deal Streak, Neurocrine Grows, & Stipple & Sidewinder Megarounds
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Apr
2026
Sidewinder Advances Bispecific ADCs for Cancer, Pockets $137M
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Apr
2026
Computation, Chemistry & Culture For Drug Discovery: Abbas Kazimi on The Long Run
Abbas Kazimi is today’s guest on The Long Run. Abbas is the CEO of Boston-based Nimbus Therapeutics. It’s a privately held company that discovers and develops oral small molecule drugs. It does this through a combination of computational chemistry, medicinal chemistry, AI, and the combined effort of a small group of talented and hardworking people. Nimbus is probably best known... Read More
6
Apr
2026
Stipple Bio, Discovering New Cancer Drug Targets, Secures $100M
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Apr
2026
Lilly Buys Centessa, Takeda & Alumis Tyk2 Showdown, & Blackstone’s Megafund
Medicines that are breaking new ground in sleep medicine, immune-mediated kidney diseases, and plaque psoriasis made headlines this week. Ten years from now, it’s possible millions of people will be living healthier, more vibrant lives because of these groundbreaking medicines. The science continues to yield dazzling results. But you have to wonder how long this sector can flourish in a... Read More
31
Mar
2026
Sleep Medicine Heats Up, as Lilly Enters Arena with Takeda, Alkermes
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
31
Mar
2026
Inspired by Mother Nature, Discovering New Drugs: Viswa Colluru on The Long Run
Viswa Colluru is today’s guest on The Long Run. Viswa is the founder and CEO of Boulder, Colo.-based Enveda. The startup company, founded in 2019, is focused on discovering and developing small molecule drugs with novel mechanisms of action. It relies on a chemistry-based approach to drug discovery, drawing inspiration from products found in nature. The privately held company has... Read More
26
Mar
2026
Merck Snaps Up New Cancer Drug, Denali Grows Up, & Gilead’s TCE Wager
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
23
Mar
2026
Merck’s Davis-Era Acquisitions: Enough for Life After Keytruda?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Mar
2026
Europe’s Biotech Investment Crisis: Otello Stampacchia on The Long Run
Otello Stampacchia is today’s guest on The Long Run. Otello is the founder and managing director of Omega Funds. It’s a transatlantic biotech venture firm with offices in Boston and Geneva, Switzerland. He’s a native of Italy and you might say a true international businessman, deeply rooted in the issues startups face in various geographies around the world. This conversation... Read More
12
Mar
2026
Servier Buys Day One, Vertex Hits IgAN Phase III, & Prasad’s Unceremonious Exit at FDA
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Mar
2026
What the Timmerman Traverse Is All About
The Timmerman Traverse has become a phenomenon in the biotech industry. Numbers tell part of the story. More than 200 biotech industry leaders have participated since 2019. More than $15 million has been raised to support high-risk/high-reward cancer research, poverty alleviation, and newborn screening for sickle cell disease. Nonprofit organizations have seen awareness of their work, and their donor networks,... Read More
10
Mar
2026
Eli Lilly’s Last 20 Acquisitions, and the Opportunity for More
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Mar
2026
Candid Goes Public, Uniqure’s FDA Dispute, & Moderna’s Big Legal Bill
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Mar
2026
Biotech’s Deep Pool of Midsized Companies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Mar
2026
T-cell Engagers for Autoimmune Disease: Ken Song on The Long Run
Ken Song is today’s guest on The Long Run. First things first, this episode was recorded before news broke that Candid Therapeutics went public via a reverse merger with RallyBio. But I must say, that deal was no surprise. Ken was on The Long Run five years ago, in November 2021. At that time, he was CEO of San Diego-based... Read More
26
Feb
2026
Gilead Acquires Arcellx, Alkermes Passes the Torch, Beam Borrows Big
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.